vs
GLADSTONE COMMERCIAL CORP（GOOD）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GLADSTONE COMMERCIAL CORP的季度营收约是REGENXBIO Inc.的1.4倍（$43.5M vs $30.3M），GLADSTONE COMMERCIAL CORP净利率更高（12.4% vs -221.3%，领先233.7%），REGENXBIO Inc.同比增速更快（43.0% vs 16.3%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 10.3%）
格拉德斯通商业公司是一家上市房地产投资信托，主要在美国境内收购、持有及运营多元化的工业与商业地产组合，面向制造、物流、医疗、专业服务等领域的租户提供长期净租赁服务，核心客群为中小规模企业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GOOD vs RGNX — 直观对比
营收规模更大
GOOD
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出26.7%
16.3%
净利率更高
GOOD
高出233.7%
-221.3%
两年增速更快
RGNX
近两年复合增速
10.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.5M | $30.3M |
| 净利润 | $5.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 12.4% | -221.3% |
| 营收同比 | 16.3% | 43.0% |
| 净利润同比 | -25.1% | -31.2% |
| 每股收益（稀释后） | $0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GOODRGNX
| Q4 25 | $43.5M | $30.3M | ||
| Q3 25 | $40.8M | $29.7M | ||
| Q2 25 | $39.5M | $21.4M | ||
| Q1 25 | $37.5M | $89.0M | ||
| Q4 24 | $37.4M | $21.2M | ||
| Q3 24 | $39.2M | $24.2M | ||
| Q2 24 | $37.1M | $22.3M | ||
| Q1 24 | $35.7M | $15.6M |
净利润GOODRGNX
| Q4 25 | $5.4M | $-67.1M | ||
| Q3 25 | $4.1M | $-61.9M | ||
| Q2 25 | $4.6M | $-70.9M | ||
| Q1 25 | $5.1M | $6.1M | ||
| Q4 24 | $7.2M | $-51.2M | ||
| Q3 24 | $11.7M | $-59.6M | ||
| Q2 24 | $1.6M | $-53.0M | ||
| Q1 24 | $3.5M | $-63.3M |
毛利率GOODRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率GOODRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率GOODRGNX
| Q4 25 | 12.4% | -221.3% | ||
| Q3 25 | 10.1% | -208.3% | ||
| Q2 25 | 11.7% | -331.8% | ||
| Q1 25 | 13.7% | 6.8% | ||
| Q4 24 | 19.2% | -241.3% | ||
| Q3 24 | 29.8% | -246.3% | ||
| Q2 24 | 4.3% | -237.7% | ||
| Q1 24 | 9.9% | -405.4% |
每股收益（稀释后）GOODRGNX
| Q4 25 | $0.05 | $-1.30 | ||
| Q3 25 | $0.02 | $-1.20 | ||
| Q2 25 | $0.03 | $-1.38 | ||
| Q1 25 | $0.04 | $0.12 | ||
| Q4 24 | $0.10 | $-0.99 | ||
| Q3 24 | $0.20 | $-1.17 | ||
| Q2 24 | $-0.04 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.8M | $230.1M |
| 总债务越低越好 | $843.5M | — |
| 股东权益账面价值 | $171.8M | $102.7M |
| 总资产 | $1.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 4.91× | — |
8季度趋势，按日历期对齐
现金及短期投资GOODRGNX
| Q4 25 | $10.8M | $230.1M | ||
| Q3 25 | $18.4M | $274.2M | ||
| Q2 25 | $11.7M | $323.3M | ||
| Q1 25 | $10.4M | $267.9M | ||
| Q4 24 | $11.0M | $234.7M | ||
| Q3 24 | $10.5M | $255.5M | ||
| Q2 24 | $10.4M | $290.4M | ||
| Q1 24 | $10.5M | $338.7M |
总债务GOODRGNX
| Q4 25 | $843.5M | — | ||
| Q3 25 | $843.3M | — | ||
| Q2 25 | $794.4M | — | ||
| Q1 25 | $740.7M | — | ||
| Q4 24 | $693.4M | — | ||
| Q3 24 | $692.6M | — | ||
| Q2 24 | $722.5M | — | ||
| Q1 24 | $719.4M | — |
股东权益GOODRGNX
| Q4 25 | $171.8M | $102.7M | ||
| Q3 25 | $184.8M | $161.5M | ||
| Q2 25 | $177.2M | $213.7M | ||
| Q1 25 | $183.2M | $274.2M | ||
| Q4 24 | $171.2M | $259.7M | ||
| Q3 24 | $168.9M | $301.4M | ||
| Q2 24 | $145.7M | $348.3M | ||
| Q1 24 | $147.3M | $390.7M |
总资产GOODRGNX
| Q4 25 | $1.2B | $453.0M | ||
| Q3 25 | $1.3B | $525.2M | ||
| Q2 25 | $1.2B | $581.0M | ||
| Q1 25 | $1.2B | $490.9M | ||
| Q4 24 | $1.1B | $466.0M | ||
| Q3 24 | $1.1B | $519.1M | ||
| Q2 24 | $1.1B | $569.4M | ||
| Q1 24 | $1.1B | $629.2M |
负债/权益比GOODRGNX
| Q4 25 | 4.91× | — | ||
| Q3 25 | 4.56× | — | ||
| Q2 25 | 4.48× | — | ||
| Q1 25 | 4.04× | — | ||
| Q4 24 | 4.05× | — | ||
| Q3 24 | 4.10× | — | ||
| Q2 24 | 4.96× | — | ||
| Q1 24 | 4.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $88.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 16.38× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GOODRGNX
| Q4 25 | $88.2M | $-52.3M | ||
| Q3 25 | $18.9M | $-56.0M | ||
| Q2 25 | $35.8M | $-49.3M | ||
| Q1 25 | $17.7M | $33.6M | ||
| Q4 24 | $57.0M | $-31.6M | ||
| Q3 24 | $5.5M | $-40.5M | ||
| Q2 24 | $13.6M | $-45.5M | ||
| Q1 24 | $15.0M | $-55.5M |
自由现金流GOODRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率GOODRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度GOODRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率GOODRGNX
| Q4 25 | 16.38× | — | ||
| Q3 25 | 4.57× | — | ||
| Q2 25 | 7.74× | — | ||
| Q1 25 | 3.44× | 5.53× | ||
| Q4 24 | 7.93× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 8.44× | — | ||
| Q1 24 | 4.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GOOD
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
